The Oncology Institute Inc. logo

The Oncology Institute Inc. (TOI)

Market Closed
2 Mar, 20:00
NASDAQ (CM) NASDAQ (CM)
$
2. 95
+0.06
+2.08%
Pre Market
$
3. 12
+0.17 +5.76%
284.32M Market Cap
- P/E Ratio
- Div Yield
1,297,910 Volume
-0.36 Eps
$ 2.89
Previous Close
Day Range
2.76 3.06
Year Range
0.6 4.88
Want to track TOI and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
TOI earnings report is expected in 2 days (5 Mar 2026)

Summary

TOI closed today higher at $2.95, an increase of 2.08% from yesterday's close, completing a monthly increase of 12.17% or $0.32. Over the past 12 months, TOI stock lost -17.13%.
TOI is not paying dividends to its shareholders.
The last earnings report, released on Nov 13, 2025, exceeded the consensus estimates by 0.12%. On average, the company has surpassed earnings expectations by 0.06%, based on the last three reports. The next scheduled earnings report is due on Mar 05, 2026.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

TOI Chart

Similar

IRD
Opus Genetics Inc.
$ 4.33
+4.09%
Benitec Biopharma Inc.
$ 10.83
-0.64%
Amarin Corporation plc - American Depositary Receipt
$ 13.93
+0.94%
Abeona Therapeutics Inc.
$ 5.06
-1.17%
Eupraxia Pharmaceuticals Inc.
$ 8.3
+1.47%
The Oncology Institute: Making Progress

The Oncology Institute: Making Progress

The Oncology Institute recently achieved its first profitable Adj. EBITDA for the month and posted 37% YoY revenue growth, beating consensus by $13.9M. TOI raised FY25 guidance to $500M revenue and expects positive Adj. EBITDA in Q4, with cash flow positivity likely by mid-2026. Despite a massive share price surge in 12 months, GAAP EPS profitability remains two years away; consolidation is expected before a favorable entry point.

Seekingalpha | 2 months ago
The Oncology Institute, Inc. (TOI) Q3 2025 Earnings Call Transcript

The Oncology Institute, Inc. (TOI) Q3 2025 Earnings Call Transcript

The Oncology Institute, Inc. ( TOI ) Q3 2025 Earnings Call November 13, 2025 5:00 PM EST Company Participants Mark Hueppelsheuser - General Counsel Daniel Virnich - CEO & Executive Director Rob Carter - Chief Financial Officer Conference Call Participants David Larsen - BTIG, LLC, Research Division Yuan Zhi - B. Riley Securities, Inc., Research Division Robert LeBoyer - NOBLE Capital Markets, Inc., Research Division Presentation Operator Greetings, and welcome to The Oncology Institute Third Quarter 2025 Earnings Call.

Seekingalpha | 3 months ago
The Oncology Institute, Inc. (TOI) Reports Q3 Loss, Beats Revenue Estimates

The Oncology Institute, Inc. (TOI) Reports Q3 Loss, Beats Revenue Estimates

The Oncology Institute, Inc. (TOI) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.18 per share a year ago.

Zacks | 3 months ago

The Oncology Institute Inc. (TOI) FAQ

What is the stock price today?

The current price is $2.95.

On which exchange is it traded?

The Oncology Institute Inc. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is TOI.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 284.32M.

When is the next earnings date?

The next earnings report will release on Mar 05, 2026.

Has The Oncology Institute Inc. ever had a stock split?

No, there has never been a stock split.

The Oncology Institute Inc. Profile

Health Care Providers & Services Industry
Healthcare Sector
Daniel Virnich CEO
NASDAQ (CM) Exchange
68236X100 CUSIP
US Country
825 Employees
- Last Dividend
- Last Split
15 Nov 2021 IPO Date

Overview

The Oncology Institute, Inc. is an American oncology company specializing in a wide range of oncology services. Founded in 2007 and headquartered in Cerritos, California, the institute is dedicated to providing comprehensive care for adult and senior cancer patients. With 67 clinic locations across the United States, it offers a broad spectrum of integrated services aimed at the management and treatment of cancer. The company's approach to cancer care includes a combination of medical oncology services, innovative therapies, and patient support programs designed to address the individual needs of each patient.

Products and Services

  • Physician Services: Consists of consultations, diagnosis, and treatment plans developed by experienced oncologists. The Oncology Institute prides itself on employing skilled physicians who are dedicated to providing personalized and comprehensive care to each patient.
  • In-house Infusion and Dispensary: Offers convenient on-site access to chemotherapy and other medication infusions. This service allows patients to receive their treatment in a comfortable and controlled environment, supervised by the institute's medical professionals.
  • Clinical Trial Services: Participates in and manages clinical trials aimed at exploring new cancer treatments and therapies. By providing access to cutting-edge clinical trials, the Oncology Institute plays a crucial role in advancing cancer research and offering hope for innovative treatment options to its patients.
  • Radiation: Includes advanced radiation therapy options as part of a comprehensive cancer treatment plan. Radiation therapy is used to target and destroy cancer cells, and is often combined with other treatments for optimal outcomes.
  • Outpatient Stem Cell Transplants and Transfusions Programs: Provides advanced treatments like stem cell transplants and blood transfusions on an outpatient basis, reducing the need for hospital stays and allowing patients to recover in the comfort of their own homes.
  • Patient Support: Focuses on the well-being of patients beyond clinical treatment, offering services that include palliative care programs designed to help manage symptoms and improve quality of life. The company recognizes the importance of holistic care and strives to support patients and their families throughout the cancer journey.

Contact Information

Address: 18000 Studebaker Road
Phone: 213 760 1328